Posts Tagged ‘IMMU’

Another Immune Company Play – Immunomedics

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Cancer is a class of diseases in which a group of cells display uncontrolled growth.  Some cancers invade or intrude upon adjacent tissues, then destroy that tissue/organ, and then spread (metastasize) to other locations in the body via lymph or blood.  These three malignant properties of cancers differentiate them from benign tumors, which do not invade or metastasize.  All of these diseases suggest that there will be a need for personalized therapy, as even within a specific type of cancer, there is wide heterogeneity in clinicopathological features.  For instance, leukemia, lymphoma, myeloma, etc are all lymphoproliferative disorders (where lymphocytes are produced in excess) affect one or more different biological pathways that play a role in lymphomagenesis (the development of B cells and T cells).  Over the past year, on focal point of our  investment virtual portfolio has been smaller companies researching and developing treatments for cancer (CRIS, ARIA, ARRY, SPPI, IMGN).  The next small company with some very interesting prospects in the pipeline is Immunomedics.

Figure 1.  Cancer Prevalence.

In our recent past, monoclonal antibodies (mAbs) were discussed in the context of a mid-tiered pharma, BIIB and smaller biotech, Immunogen (IMGN).  These companies will not be rehashed, but to re-emphasize that mAb and biologics are one of the hottest areas in in biotech.  Small molecules have are not the favorites for now (especially in cancer), and that is most likely due to early stage trials, lack of efficacy, or more likely – patent protection, as biologics/mAbs are harder to show equivolance….and thus have the potential to generate cash for years to come. 

(IMMU) based in New Jersey, is primarily focused on the development of mAb-based products for the targeted treatment of cancer, autoimmune and other diseases.  The company has a number of advanced mAbs that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents (think Inmunogen, but different 'targets').  The company has built a pipeline of therapeutic product candidates that utilize several different mechanisms of action discussed below.  The company also owns a stake in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology. …
continue reading


Tags: , ,




Wild and Crazy Options Action on AIG

Today’s tickers: AIG, IMMU, XHB & NCS

AIG - Investors displayed what can only be described as options-mania today as more than 411,000 contracts (and rising) were traded on the stock by lunchtime. Shares have exploded upwards by more than 28% to stand at the current price of $48.46. Option implied volatility, or the measure of investor uncertainty, jumped up from 114% at the opening bell to the current reading of 150%. Near-term uber-bulls were observed purchasing more than 7,500 calls as high as the September 70 strike price for an average premium of 1.20 apiece. The call premium at that strike – the highest strike price listed for the stock – has nearly doubled during the trading session. Early-bird rewards were apparent as traders who acted first thing this morning (around 10:30 am EDT) were able to purchase the same calls for just 36 cents each. Another trade of note was a bullish reversal established in the November contract. An investor shed 7,500 puts at the November 27 strike price for a premium of 2.50 apiece in order to partially finance the purchase of 7,500 calls at the higher November 55 strike for 4.10 each. The net cost of purchasing the calls was reduced to 1.60. Thus, this individual will begin to realize profits if AIG continues higher by 17% to breach the breakeven point at $56.60 by expiration in November. – American International Group, Inc. –

IMMU - The biopharmaceutical company’s shares have surged 60% higher to reach a new 52-week high of $6.82. Bullish movement in the stock was fueled by news regarding the firm’s experimental epratuzumab drug. Apparently, the drug showed a clinically “meaningful treatment effect” as compared with the placebo in patients with lupus. Option traders responded by positioning for continued upward momentum in IMMU. Call options were coveted at the near-term September 7.5 strike price more than 5,600 times for an average premium of 43 cents per contract. Investors holding the calls are hoping to see the stock rise 16% higher to surpass the breakeven point at $7.93 by expiration next month. Additional bullish action was observed at the November 5.0 strike price where traders shed 2,900 puts for 46 cents a-pop. Perhaps these individuals doubt that shares will slip beneath $5.00 by November’s expiration day. Thus, they are happy to receive the 46 cents premium in exchange for bearing the risk that shares of the…
continue reading


Tags: , , ,




Bearish Put-Spreader Paws Profits at Merck

Today’s tickers: MRK, IMMU, AET, ODP, FSLR, EEM, MFA & XLI

MRK – The pharmaceutical company declared a quarterly dividend of 38 cents per share for the fourth quarter of 2009 today, amid a 3% decline in shares to arrive at the current price of $29.81. A bearish put spread established in the October contract suggests some investors are wary of further declines for the company. The spread involved the purchase of 7,400 puts at the October 31 strike price for 2.23 apiece against the sale of 7,400 puts at the lower October 29 strike for a premium of 1.28 each. The net cost of the transaction amounts to 95 cents, yielding the investor maximum potential profits of 1.05 if the stock slips to $29.00 by expiration. The current market price of MRK is currently lower than the breakeven point on the trade of $30.05. Thus, the investor responsible for the spread has already earned 24 cents by assuming a bearish stance on the stock. – Merck & Company, Inc.

IMMU – Shares of the biopharmaceutical company engaged in the development of products designed to treat cancer, autoimmune, and other serious diseases, have surged more than 14% to $5.24 during the trading session. Bullish movement in the stock was fueled by the news that IMMU has entered into a partnership and cross-licensing agreement with Alexis Biotech Ltd., of London, England. The firms are combining efforts in order to develop “targeted vaccines against cancers” such as melanoma and chronic lymphocytic leukemia, as well as infectious diseases such as AIDS. Option traders hoping for continued upward movement in the price of the underlying were seen getting long of bullish call options in the September contract. The September 7.5 strike price had approximately 3,500 calls coveted for 38 cents apiece. Investors holding the calls will begin to realize profits in the event that shares climb another 50% to surpass the breakeven point at $7.88 by expiration. – Immunomedics, Inc.

AET – The third-largest health insurer in the United States has enjoyed a rally in shares of more than 13% to $29.08 this afternoon after receiving an upgrade to ‘outperform’ from ‘neutral’ at Cowen and Company. Call options exchanged on the stock today exceeded the number of puts by a factor of more than 3-to-1, reflecting bullish sentiment by investors. The near-term August 30 strike price had more than 8,800 calls purchased for
continue reading


Tags: , , , , , , ,




 
 
 

Phil's Favorites

Identifying a fake picture online is harder than you might think

 

Identifying a fake picture online is harder than you might think

If you know how photo editing works, you might have a leg up at spotting fakes. Gorodenkoff/Shutterstock.com

Courtesy of Mona Kasra, University of Virginia

It can be hard to tell whether a picture is real. Consider, as the participants in our recent research did, these two images and see whether you think neither, either or both of them has been doctored.

...



more from Ilene

Zero Hedge

Shocking Before & After Photos Reveal Awful Truth About Widespread US Crop Failures In 2019

Courtesy of Michael Snyder, The Economic Collapse

Torrential rains have been hammering the heartland of America for months, and at this point vast stretches of farmland in the middle of the country are nothing but mud.  As a result of the endless rain and unprecedented flooding that we have witnessed, millions of acres of farmland will have nothing planted on them at all in 2019, and that is a major national crisis.  But most farmers were able to get seeds planted in the deplorable conditions, and now they are desperately hoping that something will actually grow.  Unfortunately, on farm after farm what is coming out of the ground looks absolutely terrible.  Even if we get ideal weather conditions for the rest of the summer, there is no way that many of t...



more from Tyler

Kimble Charting Solutions

Wilshire 5000 Creating A Triple Top? An Important Breakout Test Is In Play!

Courtesy of Chris Kimble.

The stock market has been on fire of late, rallying up to the edge of price resistance on several indexes. Today, we look at one of those stock market indexes: the Wilshire 5000.

The Wilshire 5000 tracks all of the stocks in the US market, so it is a broad-based index that carries significant importance when gauging the health of the overall US stock market.

Looking at the long-term “weekly” chart above, it is pretty clear that the index is at an important price juncture.

The Wilshire 5000 spent the last 25 years trading within a rising price channel (1)...



more from Kimble C.S.

Insider Scoop

Jefferies Upgrades Deere, Cites 'Significantly Improved Farmer Income Outlook'

Courtesy of Benzinga.

Farmer buying power will remain pressured for 2019, but this will change for the better next year and will help support Deere & Company (NYSE: DE), according to Jefferies.

The Analyst

Jefferies' Stephen Volkmann upgraded Deere from Hold to Buy with a price target lifted from $150 to $190....



http://www.insidercow.com/ more from Insider

Chart School

Formula for when the Great Stock Market Rally ends

Courtesy of Read the Ticker.

When valuations for the boring water company or the boring electric company is trading like your Facebook, Apple, Amazon or Netflix or Google (ie FANG) you know something is wrong.

This is when a seriously over valued market is screaming at you.

Of course the reader must understand in a world where money printing goes super nuts (Zimbabwe style) the stock market may go hyper inflationary and picking a time frame for a top is never a good idea, but we are not there yet. There is no Ben Bernanke helicopter money to the masses yet (ie MMT). 

To see when water company's (and such like) are nearing the crazy FANG like valuations a review of the Dow Jones Utility Index channel shows us how history can repeat. The c...

more from Chart School

ValueWalk

The "Tesla Killer" Car Is Nowhere In Sight

 

The “Tesla Killer” Car Is Nowhere In Sight

By Jacob Wolinsky, ValueWalk

Here’s some catnip for the Tesla bulls on this email list: my analyst, Kevin DeCamp, a longtime TSLA shareholder and car owner, took a test drive of the Jaguar I-PACE and, while it “looks great and is fun to drive… it is lacking in a few areas where Tesla really shines.” He concludes that “Tesla may end up killing itself, but the “Tesla killer” car is nowhere in sight.”

The Tesla Killer Hasn’t Arrived Yet: My Test Drive of the Jaguar I-PACE

By Kevin DeCamp

As a long-time, devoted Tesla...



more from ValueWalk

Digital Currencies

Cryptocurrencies are finally going mainstream - the battle is on to bring them under global control

 

Cryptocurrencies are finally going mainstream – the battle is on to bring them under global control

The high seas are getting lower. dianemeise

Courtesy of Iwa Salami, University of East London

The 21st-century revolutionaries who have dominated cryptocurrencies are having to move over. Mainstream financial institutions are adopting these assets and the blockchain technology that enables them, in what ...



more from Bitcoin

Biotech

Consumer genetic testing customers stretch their DNA data further with third-party interpretation websites

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

 

Consumer genetic testing customers stretch their DNA data further with third-party interpretation websites

If you’ve got the raw data, why not mine it for more info? Sergey Nivens/Shutterstock.com

Courtesy of Sarah Catherine Nelson, University of Washington

Back in 2016, Helen (a pseudonym) took three different direct-to-consumer (DTC) genetic tests: AncestryDNA, 23andMe and FamilyTreeDNA. She saw genetic testing as a way...



more from Biotech

Members' Corner

Despacito - How to Make Money the Old-Fashioned Way - SLOWLY!

Are you ready to retire?  

For most people, the purpose of investing is to build up enough wealth to allow you to retire.  In general, that's usually enough money to reliably generate a year's worth of your average income, each year into your retirement so that that, plus you Social Security, should be enough to pay your bills without having to draw down on your principle.

Unfortunately, as the last decade has shown us, we can't count on bonds to pay us more than 3% and the average return from the stock market over the past 20 years has been erratic - to say the least - with 4 negative years (2000, 2001, 2002 and 2008) and 14 positives, though mostly in the 10% range on the positives.  A string of losses like we had from 2000-02 could easily wipe out a decades worth of gains.

Still, the stock market has been better over the last 10 (7%) an...



more from Our Members

Mapping The Market

It's Not Capitalism, it's Crony Capitalism

A good start from :

It's Not Capitalism, it's Crony Capitalism

Excerpt:

The threat to America is this: we have abandoned our core philosophy. Our first principle of this nation as a meritocracy, a free-market economy, where competition drives economic decision-making. In its place, we have allowed a malignancy to fester, a virulent pus-filled bastardized form of economics so corrosive in nature, so dangerously pestilent, that it presents an extinction-level threat to America – both the actual nation and the “idea” of America.

This all-encompassing mutant corruption saps men’s souls, crushes opportunities, and destroys economic mobility. Its a Smash & Grab system of ill-gotten re...



more from M.T.M.

OpTrader

Swing trading portfolio - week of September 11th, 2017

Reminder: OpTrader is available to chat with Members, comments are found below each post.

 

This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current  trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).

We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options. 

Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.

To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here ...



more from OpTrader

Promotions

Free eBook - "My Top Strategies for 2017"

 

 

Here's a free ebook for you to check out! 

Phil has a chapter in a newly-released eBook that we think you’ll enjoy.

In My Top Strategies for 2017, Phil's chapter is Secret Santa’s Inflation Hedges for 2017.

This chapter isn’t about risk or leverage. Phil present a few smart, practical ideas you can use as a hedge against inflation as well as hedging strategies designed to assist you in staying ahead of the markets.

Some other great content in this free eBook includes:

 

·       How 2017 Will Affect Oil, the US Dollar and the European Union

...

more from Promotions





About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>


As Seen On:




About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

Market Shadows >>